Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 56 29 6 17
Adverse Event Associated with Cardiac Arrhythmia 71
Premature Cardiac Complex 71
Extrasystoles 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
cardiac arrhythmia:
Clinical modifier sudden death
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 56 115000
ICD10 32 I49.8 I49.9
MedGen 41 C0003811
SNOMED-CT via HPO 68 263681008 26636000 88425004
UMLS 71 C0340464 C1560249

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to long qt syndrome 15 and cardiac conduction defect, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

More information from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 573)
# Related Disease Score Top Affiliating Genes
1 long qt syndrome 15 32.1 KCNJ2 CACNA1C
2 cardiac conduction defect 32.0 SCN5A RYR2 KCNQ1 KCNH2 ANK2
3 cardiac arrhythmia, ankyrin-b-related 31.7 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
4 arrhythmogenic right ventricular dysplasia, familial, 8 31.6 RYR2 PKP2
5 familial short qt syndrome 31.5 KCNQ1 KCNJ2 KCNH2
6 ventricular fibrillation, paroxysmal familial, 1 31.4 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
7 long qt syndrome 14 31.3 SCN5A KCNQ1 KCNJ2 KCNH2 CACNA1C
8 progressive familial heart block, type ia 31.1 SCN5A ANK2
9 syncope 30.9 SCN5A RYR2 KCNQ1 KCNH2
10 long qt syndrome 6 30.8 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
11 brugada syndrome 1 30.5 SCN5A RYR2 KCNH2 AKAP9
12 atrial fibrillation 30.4 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
13 sick sinus syndrome 30.3 SCN5A RANGRF KCNQ1 KCNJ2 CACNA1C ANK2
14 sudden infant death syndrome 30.3 SCN5A RYR2 KCNQ1 KCNH2
15 atrial standstill 1 30.3 SCN5A RYR2 PKP2
16 long qt syndrome 13 30.3 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 ANK2
17 long qt syndrome 12 30.3 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 ANK2
18 third-degree atrioventricular block 30.3 SCN5A KCNJ2 KCNH2
19 long qt syndrome 11 30.3 KCNQ1 KCNJ2 KCNE2 CACNA1C ANK2 AKAP9
20 first-degree atrioventricular block 30.2 SCN5A KCNJ2
21 left bundle branch hemiblock 30.2 SCN5A RYR2 PKP2
22 long qt syndrome 9 30.2 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
23 atrioventricular block 30.1 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
24 brugada syndrome 4 30.0 SCN5A KCNQ1 KCNJ2 KCNH2 CACNA1C
25 brugada syndrome 3 29.9 KCNE2 CACNA1C-AS1 CACNA1C ANK2
26 hyperkalemic periodic paralysis 29.9 SCN5A KCNJ2
27 cardiac arrest 29.9 SCN5A RYR2 KCNQ1 KCNH2 ANK2 AKAP9
28 long qt syndrome 3 29.9 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
29 andersen cardiodysrhythmic periodic paralysis 29.8 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
30 long qt syndrome 5 29.7 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
31 congestive heart failure 29.6 SCN5A RYR2 KCNQ1 KCNJ2 KCNE2 CACNA1C
32 hypokalemic periodic paralysis, type 1 29.6 SCN5A KCNJ2 CACNA1C
33 wolff-parkinson-white syndrome 29.6 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
34 familial long qt syndrome 29.5 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
35 right bundle branch block 29.4 SCN5A RANGRF PKP2 KCNH2 CACNA1C
36 chromosome 2q35 duplication syndrome 29.3 KCNQ1 KCNJ2 CACNA1C
37 long qt syndrome 2 29.1 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
38 noonan syndrome with multiple lentigines 28.9 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
39 long qt syndrome 1 28.7 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
40 sinoatrial node disease 28.6 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
41 arrhythmogenic right ventricular cardiomyopathy 28.6 SCN5A RYR2 PKP2 KCNH2 CACNA1C ANK2
42 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 28.3 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
43 heart disease 28.2 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
44 jervell and lange-nielsen syndrome 1 28.2 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
45 short qt syndrome 27.7 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
46 hypertrophic cardiomyopathy 27.6 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
47 dilated cardiomyopathy 27.6 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
48 brugada syndrome 27.5 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
49 long qt syndrome 27.2 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
50 timothy syndrome 26.8 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation First-Degree Atrioventricular Block
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 31 HP:0006696

Symptoms via clinical synopsis from OMIM:

56
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM:

115000

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1 PKP2
2 muscle MP:0005369 9.23 CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1 PKP2

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 289)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
6
Ibutilide Approved Phase 4 122647-32-9, 122647-31-8 60753
7
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
8
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Methadone Approved Phase 4 76-99-3 4095
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
13
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
14
Vancomycin Approved Phase 4 1404-90-6 14969 441141
15
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
16
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
17
Adenosine Approved, Investigational Phase 4 58-61-7 60961
18
Histamine Approved, Investigational Phase 4 51-45-6 774
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
21
Bisoprolol Approved Phase 4 66722-44-9 2405
22
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
23
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
24
Metformin Approved Phase 4 657-24-9 14219 4091
25
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Glucagon Approved Phase 4 16941-32-5
28
Insulin aspart Approved Phase 4 116094-23-6 16132418
29
Insulin glargine Approved Phase 4 160337-95-1
30
Insulin lispro Approved Phase 4 133107-64-9
31
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
32
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
33
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
34
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
35
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
36
nivolumab Approved Phase 4 946414-94-4
37
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
39
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
40
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
41 Tocotrienol Investigational Phase 4 6829-55-6
42 Dopamine Agents Phase 4
43 Dopamine agonists Phase 4
44 Dopamine Antagonists Phase 4
45 Serotonin 5-HT1 Receptor Agonists Phase 4
46 Antipsychotic Agents Phase 4
47 Quetiapine Fumarate Phase 4 111974-72-2
48 Adrenergic beta-Agonists Phase 4
49 Adrenergic alpha-Agonists Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 345)
# Name Status NCT ID Phase Drugs
1 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
2 Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
3 Study on the Role of a Combination of Nutraceuticals (Ritmonutra) With an Effect on Benign Supraventricular and Ventricular Arrhythmias in Subjects Free of a Specific Organic Heart Disease. Completed NCT01647984 Phase 4
4 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics: a Double-blind "Split-mouth" Controlled Trial. Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
5 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
6 Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study Completed NCT01628666 Phase 4 Incremental;Conventional
7 Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study Completed NCT01613092 Phase 4 Incremental;Cefazolin
8 CRYptogenic STroke And underLying AF Trial Completed NCT00924638 Phase 4
9 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases Completed NCT00851279 Phase 4
10 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
11 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After Endoscopic Variceal Ligation: A Randomised Controlled Clinical Trial Completed NCT03584087 Phase 4 Normal Saline;Terlipressin
12 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
13 Supportive Measures in Treatment of Aluminum Phosphide Poisoning as a Trial to Reduce Mortality at Assiut University Hospital Completed NCT03879356 Phase 4 N-acetyl cysteine
14 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
15 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
16 Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids Completed NCT01967433 Phase 4 Diphenhydramine;Placebo
17 Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training Completed NCT00922493 Phase 4
18 The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation: Single Center, Prospective, Double-Blind and Randomized Study Completed NCT02359370 Phase 4 Lidocaine;Magnesium Sulphate
19 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
20 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
21 Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial Completed NCT00597077 Phase 4
22 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
23 FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR Completed NCT01524705 Phase 4 "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)];Insulin glargine, metformin, prandial insulin
24 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
25 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
26 Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure: the SWISS-APERO Randomized Clinical Trial Recruiting NCT03399851 Phase 4
27 Interaction Between Intravenous Magnesium Sulphate and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block - A Randomized, Double Blinded, Electrophysiological Study Recruiting NCT03497923 Phase 4 Magnesium Sulfate
28 Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study) Recruiting NCT02426944 Phase 4 NOAC
29 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Active, not recruiting NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
30 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
31 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
32 A Multicenter, Randomized, Double-Blind, Controlled Study of EXPAREL for Postsurgical Pain Management in Subjects Undergoing Open Lumbar Spinal Fusion Surgery Terminated NCT03015961 Phase 4 Bupivacaine HCl;EXPAREL and bupivacaine HCl
33 Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation Terminated NCT01546883 Phase 4 Dabigatran etexilate (Pradaxa)
34 Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate Withdrawn NCT00817830 Phase 4 lodenafil carbonate
35 Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance Withdrawn NCT02120560 Phase 4
36 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
37 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
38 Influence of a Specific Micronutrient Combination on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia Completed NCT02652338 Phase 3
39 Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation : Randomised Controlled Double Blind Study (LOMAGHI Study) Completed NCT00965874 Phase 3 Magnesium Sulfate high dose;Magnesium Sulfate low dose;Placebos
40 Digitalis Investigation Group (DIG) Completed NCT00000476 Phase 3 digitalis
41 Cardiac Arrhythmia Suppression Trial (CAST) Completed NCT00000526 Phase 3 encainide;flecainide;moricizine
42 Study on Omega-3 Fatty Acids and Ventricular Arrhythmia, a Parallel, Placebo-Controlled, Double Blind Intervention Study Completed NCT00110838 Phase 3
43 Beta-Blocker Evaluation in Survival Trial (BEST) Completed NCT00000560 Phase 3 adrenergic beta antagonists
44 Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) Completed NCT00000558 Phase 3 angiotensin-converting enzyme inhibitors
45 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation Completed NCT02132767 Phase 3 Amiodarone;Rate Control
46 A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension Completed NCT00461903 Phase 3 Perindopril
47 CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation Completed NCT00007605 Phase 3 Amiodarone;Sotalol
48 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
49 Comparing Intranasal Dexmedetomidine With Oral Midazolam as Premedication for Older Children Undergoing General Anesthesia for Dental Rehabilitation Completed NCT02250703 Phase 3 Midazolam;Dexmedetomidine
50 Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed NCT00000556 Phase 3 amiodarone;sotalol;propafenone;flecainide;quinidine;moricizine;disopyramide;procainamide;adrenergic beta antagonists;verapamil;diltiazem;digoxin

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 29

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

40
Heart, Testes, Lung, Kidney, Brain, Liver, Thyroid

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 5566)
# Title Authors PMID Year
1
KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population. 6
12442276 2002
2
Familial paroxysmal ventricular tachycardia in two sisters. 56
4129426 1974
3
Fatal familial cardiac arrhythmias. Histologic observations on the cardiac conduction system. 56
5016833 1972
4
FAMILIAL POLYTOPIC AND POLYMORPHIC EXTRASYSTOLES. 56
14115011 1964
5
Arrhythmogenic risks of stem cell replacement therapy for cardiovascular diseases. 61
31994198 2020
6
Non-invasive ablation of cardiac arrhythmia. Is proton radiation therapy a step forward? 61
32345505 2020
7
Specific recognition of ion channel blocker by high-content cardiomyocyte electromechanical integrated correlation. 61
32452396 2020
8
Arrhythmia susceptibility in a rat model of acute atrial dilation. 61
32063273 2020
9
IDDCA syndrome in a Chinese infant due to GNB5 biallelic mutations. 61
32203251 2020
10
Crosstalk between PKC and MAPK pathway activation in cardiac fibroblasts in a rat model of atrial fibrillation. 61
32095918 2020
11
Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After an Intracranial Hemorrhage. 61
31985523 2020
12
The antiarrhythmic compound efsevin directly modulates voltage-dependent anion channel 2 by binding to its inner wall and enhancing mitochondrial Ca2+ uptake. 61
32059260 2020
13
Computer Aided Diagnosis for atrial fibrillation based on new artificial adaptive systems. 61
32146212 2020
14
Genetic characterization and long-term management of severely affected siblings with intellectual developmental disorder with cardiac arrhythmia syndrome. 61
32280589 2020
15
Evaluation of Clinical Practices Related to Variants of Uncertain Significance Results in Inherited Cardiac Arrhythmia and Inherited Cardiomyopathy Genes. 61
32522017 2020
16
Aberrant cardiac metabolism leads to cardiac arrhythmia. 61
32472752 2020
17
Junctional ectopic tachycardia in neonatal enterovirus myocarditis. 61
32577248 2020
18
Corrigendum to: Cardiac arrhythmia services in Africa from 2011 to 2018: the second report from the Pan African Society of Cardiology working group on cardiac arrhythmias and pacing. 61
32533181 2020
19
Artificial intelligence-assisted analysis on the association between exposure to ambient fine particulate matter and incidence of arrhythmias in outpatients of Shanghai community hospitals. 61
32334122 2020
20
Cardiac complications of thyroid hormone resistance syndromes. 61
32513415 2020
21
Cloud-based ECG monitoring using event-driven ECG acquisition and machine learning techniques. 61
32524444 2020
22
Impaired peroxisomal import in Drosophila oenocytes causes cardiac dysfunction by inducing upd3 as a peroxikine. 61
32523050 2020
23
High prevalence of neurological sequelae and multiple chemical sensitivity among occupants of a Finnish police station damaged by dampness microbiota. 61
32544007 2020
24
Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management. 61
32497457 2020
25
Do acute changes in ambient air pollution increase the risk of potentially fatal cardiac arrhythmias in patients with implantable cardioverter defibrillators? 61
32552837 2020
26
The atrial FibriLlatiOn real World management registry in the Middle East and Africa: design and rationale. 61
32576751 2020
27
Cardiac autonomic modulation in drug-resistant epilepsy patients after vagus nerve stimulation therapy. 61
32557527 2020
28
Cardiac synchronization and arrhythmia during irreversible electroporation. 61
32483842 2020
29
Sodium channel β1 subunits are post-translationally modified by tyrosine phosphorylation, S-palmitoylation, and regulated intramembrane proteolysis. 61
32503841 2020
30
Detecting Atrial Fibrillation and Atrial Flutter in Daily Life Using Photoplethysmography Data. 61
31689222 2020
31
Intraoperative fluid therapy and postoperative complications during minimally invasive esophagectomy for esophageal cancer: a single-center retrospective study. 61
32232660 2020
32
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. 61
32356626 2020
33
LUF7244 plus Dofetilide Rescues Aberrant Kv11.1 Trafficking and Produces Functional IKv11.1. 61
32241959 2020
34
Raising awareness and early detection of atrial fibrillation, an experience resorting to mobile technology centred on informed individuals. 61
31473110 2020
35
Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation-the REFLEC-CR Study. 61
32236859 2020
36
Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies. 61
32544502 2020
37
Skin sympathetic nerve activity in patients with obstructive sleep apnea. 61
32569836 2020
38
[The clinical characteristics and surgical management of ciliated muconodular papillary tumor]. 61
32575946 2020
39
Adjusted tight control blood glucose management in diabetic patients undergoing on pump coronary artery bypass graft. A randomized clinical trial. 61
32550193 2020
40
Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option? 61
32405924 2020
41
CHOICES IN ANTITHROMBOTIC MANAGEMENT FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. QUESTIONS (AND ANSWERS) IN CHRONOLOGICAL SEQUENCE. 61
32379867 2020
42
Acute Cardiovascular Effects of Non-Invasive Electrical Spinal Cord Stimulation: Results from a Pilot Study in Humans. 61
32378161 2020
43
[Quality and performance in cardiac pacing and electrophysiology. An update to the 2010 Italian Association of Arrhythmology and Cardiac Pacing (AIAC) - Italian Federation of Cardiology (IFC) Document 'Structure and functional organization of Arrhythmology']. 61
32310930 2020
44
Automated pre-screening of arrhythmia using hybrid combination of Fourier-Bessel expansion and LSTM. 61
32421653 2020
45
Explaining sudden infant death with cardiac arrhythmias: Complete exon sequencing of nine cardiac arrhythmia genes in Dutch SIDS cases highlights new and known DNA variants. 61
32145446 2020
46
Reduction in Cardiac Arrhythmias Within an Enhanced Recovery After Surgery Program in Colorectal Surgery. 61
31228081 2020
47
Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy. 61
32422068 2020
48
Transforming Growth Factor Beta3 is Required for Cardiovascular Development. 61
32456345 2020
49
Factors that influence marital satisfaction in men with a heart rhythm disorders. 61
32462954 2020
50
Burden and correlates of atrial fibrillation among hypertensive patients attending a tertiary hospital in Tanzania. 61
32429855 2020

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 109) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PKP2 NM_001005242.3(PKP2):c.235C>T (p.Arg79Ter)SNV Pathogenic 6754 rs121434420 12:33031955-33031955 12:32879021-32879021
2 PKP2 NM_001005242.3(PKP2):c.1211dup (p.Val406fs)duplication Pathogenic 45015 rs397516989 12:33003866-33003867 12:32850932-32850933
3 KCNQ1 NM_181798.1(KCNQ1):c.962del (p.Pro321fs)deletion Pathogenic 52977 rs397508087 11:2610029-2610029 11:2588799-2588799
4 KCNQ1 NM_181798.1(KCNQ1):c.1461_1463del (p.His487del)deletion Pathogenic 53020 rs397508101 11:2869042-2869044 11:2847812-2847814
5 KCNH2 NM_172057.2(KCNH2):c.2116del (p.Gln706fs)deletion Pathogenic 200709 rs794728472 7:150644432-150644432 7:150947344-150947344
6 KCNH2 NM_172057.2(KCNH2):c.2085_2092dup (p.Val698fs)duplication Pathogenic 200705 rs794728470 7:150644455-150644456 7:150947367-150947368
7 KCNH2 NM_172057.2(KCNH2):c.2076_2079dup (p.Pro694fs)duplication Pathogenic 200699 rs794728467 7:150644468-150644469 7:150947380-150947381
8 KCNH2 NM_172057.2(KCNH2):c.2059dup (p.Leu687fs)duplication Pathogenic 200695 rs794728465 7:150644488-150644489 7:150947400-150947401
9 KCNH2 NM_000238.4(KCNH2):c.2966-2_2967dupduplication Pathogenic 200691 rs794728464 7:150644600-150644601 7:150947512-150947513
10 KCNH2 NM_172057.2(KCNH2):c.1763_1769del (p.Gly588fs)deletion Pathogenic 200676 rs794728457 7:150644870-150644876 7:150947782-150947788
11 KCNH2 NM_172057.2(KCNH2):c.1757del (p.Pro586fs)deletion Pathogenic 200674 rs794728456 7:150644882-150644882 7:150947794-150947794
12 KCNH2 NM_172056.2(KCNH2):c.2053del (p.Arg685fs)deletion Pathogenic 200791 rs794728500 7:150648101-150648101 7:150951013-150951013
13 KCNH2 NM_172056.2(KCNH2):c.1815del (p.Ser606fs)deletion Pathogenic 200789 rs794728499 7:150648666-150648666 7:150951578-150951578
14 KCNH2 NM_172056.2(KCNH2):c.1201_1204dup (p.His402fs)duplication Pathogenic 200630 rs794728434 7:150649865-150649866 7:150952777-150952778
15 KCNH2 NM_172056.2(KCNH2):c.1142del (p.Gly381fs)deletion Pathogenic 200785 rs794728497 7:150649928-150649928 7:150952840-150952840
16 KCNH2 NM_172056.2(KCNH2):c.853_859del (p.Ala285fs)deletion Pathogenic 200618 rs794728428 7:150655204-150655210 7:150958116-150958122
17 KCNH2 NM_172056.2(KCNH2):c.809_812delinsAAAAGC (p.Thr270fs)indel Pathogenic 200614 rs794728426 7:150655251-150655254 7:150958163-150958166
18 KCNH2 NM_172056.2(KCNH2):c.735_754dup (p.Arg252fs)duplication Pathogenic 200612 rs794728425 7:150655308-150655309 7:150958220-150958221
19 KCNH2 NM_172056.2(KCNH2):c.373_374insGTGG (p.Phe125fs)insertion Pathogenic 200759 rs794728489 7:150656758-150656759 7:150959670-150959671
20 KCNH2 NM_172056.2(KCNH2):c.244_252dup (p.Ile82_Gln84dup)duplication Pathogenic 200717 rs794728476 7:150671853-150671854 7:150974765-150974766
21 KCNH2 NM_172056.2(KCNH2):c.154del (p.Cys52fs)deletion Pathogenic 200809 rs794728508 7:150671952-150671952 7:150974864-150974864
22 KCNH2 NM_172056.2(KCNH2):c.106del (p.Val36fs)deletion Pathogenic 200807 rs794728507 7:150672000-150672000 7:150974912-150974912
23 KCNH2 NM_172056.2(KCNH2):c.100del (p.Ala34fs)deletion Pathogenic 200805 rs794728506 7:150672006-150672006 7:150974918-150974918
24 KCNQ1 NM_000218.2(KCNQ1):c.165_187del (p.Gly57fs)deletion Pathogenic 200889 rs794728563 11:2466490-2466512 11:2445260-2445282
25 PKP2 NM_004572.3(PKP2):c.2013del (p.Lys672fs)deletion Pathogenic 202022 rs764817683 12:32974422-32974422 12:32821488-32821488
26 TANGO2 NM_152906.7(TANGO2):c.460G>A (p.Gly154Arg)SNV Pathogenic 208823 rs752298579 22:20049061-20049061 22:20061538-20061538
27 TANGO2 NM_152906.5(TANGO2):c.57-1743_*10769deldeletion Pathogenic 224770 22:20029135-20062954 22:20041612-20075431
28 TANGO2 NM_152906.5(TANGO2):c.146-3605_451+2245deldeletion Pathogenic 224772 22:20048857-20058261
29 TANGO2 NM_152906.7(TANGO2):c.605+1G>ASNV Pathogenic/Likely pathogenic 208824 rs372949028 22:20049207-20049207 22:20061684-20061684
30 PKP2 NM_004572.3(PKP2):c.14del (p.Gly5fs)deletion Pathogenic/Likely pathogenic 45027 rs397516996 12:33049652-33049652 12:32896718-32896718
31 RYR2 NM_001035.3(RYR2):c.14314G>A (p.Gly4772Ser)SNV Likely pathogenic 36734 rs193922622 1:237972216-237972216 1:237808916-237808916
32 RYR2 NM_001035.3(RYR2):c.4040T>G (p.Met1347Arg)SNV Likely pathogenic 36742 rs193922625 1:237754172-237754172 1:237590872-237590872
33 SCN5A NM_000335.5(SCN5A):c.3305C>A (p.Ser1102Tyr)SNV risk factor 9393 rs7626962 3:38620907-38620907 3:38579416-38579416
34 KCNE2 NM_172201.1(KCNE2):c.161T>C (p.Met54Thr)SNV risk factor 6053 rs74315447 21:35742938-35742938 21:34370639-34370639
35 KCNE2 NM_172201.1(KCNE2):c.170T>C (p.Ile57Thr)SNV Conflicting interpretations of pathogenicity 6054 rs74315448 21:35742947-35742947 21:34370648-34370648
36 ANK2 NM_001148.6(ANK2):c.11231C>A (p.Thr3744Asn)SNV Conflicting interpretations of pathogenicity 18057 rs121912705 4:114288920-114288920 4:113367764-113367764
37 ANK2 NM_001148.6(ANK2):c.11716C>T (p.Arg3906Trp)SNV Conflicting interpretations of pathogenicity 18059 rs121912706 4:114294462-114294462 4:113373306-113373306
38 ANK2 NM_001148.6(ANK2):c.8166G>A (p.Met2722Ile)SNV Conflicting interpretations of pathogenicity 35691 rs193922637 4:114277940-114277940 4:113356784-113356784
39 CACNA1C NM_000719.7(CACNA1C):c.6031G>A (p.Val2011Ile)SNV Conflicting interpretations of pathogenicity 35770 rs193922615 12:2797859-2797859 12:2688693-2688693
40 CACNA1C NM_000719.7(CACNA1C):c.6307G>T (p.Ala2103Ser)SNV Conflicting interpretations of pathogenicity 35771 rs193922616 12:2800255-2800255 12:2691089-2691089
41 AKAP9 NM_147185.3(AKAP9):c.4837A>G (p.Met1613Val)SNV Conflicting interpretations of pathogenicity 35670 rs193922723 7:91670132-91670132 7:92040818-92040818
42 JUP NM_002230.4(JUP):c.909+6C>TSNV Conflicting interpretations of pathogenicity 36426 rs193922705 17:39923625-39923625 17:41767373-41767373
43 KCNH2 NM_172057.2(KCNH2):c.2120G>T (p.Arg707Leu)SNV Conflicting interpretations of pathogenicity 36429 rs36210421 7:150644428-150644428 7:150947340-150947340
44 RYR2 NM_001035.3(RYR2):c.5586C>T (p.Asp1862=)SNV Conflicting interpretations of pathogenicity 36745 rs193922628 1:237778014-237778014 1:237614714-237614714
45 RYR2 NM_001035.3(RYR2):c.3251G>A (p.Arg1084Lys)SNV Conflicting interpretations of pathogenicity 36740 rs193922624 1:237729903-237729903 1:237566603-237566603
46 SCN1B NM_199037.3(SCN1B):c.751G>A (p.Val251Ile)SNV Conflicting interpretations of pathogenicity 36757 rs193922728 19:35524946-35524946 19:35034042-35034042
47 SCN5A NM_000335.5(SCN5A):c.4434+13C>TSNV Conflicting interpretations of pathogenicity 36762 rs148598985 3:38597919-38597919 3:38556428-38556428
48 SNTA1 NM_003098.2(SNTA1):c.311-6G>CSNV Conflicting interpretations of pathogenicity 36777 rs139532210 20:32026838-32026838 20:33439032-33439032
49 AKAP9 NM_005751.4(AKAP9):c.7034_7036del (p.Arg2345_Glu2346delinsLys)deletion Conflicting interpretations of pathogenicity 190490 rs786205709 7:91708481-91708483 7:92079167-92079169
50 ANK2 NM_001148.6(ANK2):c.10901T>A (p.Val3634Asp)SNV Conflicting interpretations of pathogenicity 67599 rs66785829 4:114286207-114286207 4:113365051-113365051

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 KCNQ1 KCNJ2 KCNH2 GNB5 AKAP9
2
Show member pathways
12.44 RYR2 KCNQ1 KCNJ2 GNB5 CACNA1C
3
Show member pathways
12.34 SCN5A RYR2 RANGRF KCNQ1 KCNJ2 KCNH2
4
Show member pathways
12.2 SCN5A RYR2 KCNQ1 CACNA1C
5 12.16 KCNQ1 KCNJ2 KCNH2 KCNE2 GNB5 CACNA1C
6
Show member pathways
11.91 KCNQ1 KCNJ2 KCNE2
7
Show member pathways
11.86 RYR2 PKP2 CACNA1C
8 11.83 SCN5A RYR2 KCNQ1 KCNH2
9
Show member pathways
11.82 KCNQ1 KCNJ2 KCNH2
10
Show member pathways
11.51 SCN5A RANGRF KCNQ1 KCNE2 CACNA1C AKAP9
11 11 SCN5A ANK2
12 10.97 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
13 10.74 KCNQ1 KCNJ2

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.11 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
2 Z disc GO:0030018 9.62 SCN5A RYR2 CACNA1C ANK2
3 sarcolemma GO:0042383 9.56 SCN5A RYR2 CACNA1C ANK2
4 T-tubule GO:0030315 9.46 SCN5A KCNJ2 CACNA1C ANK2
5 smooth endoplasmic reticulum GO:0005790 9.4 RYR2 KCNJ2
6 voltage-gated potassium channel complex GO:0008076 9.35 KCNQ1 KCNJ2 KCNH2 KCNE2 AKAP9
7 intercalated disc GO:0014704 9.02 SCN5A RANGRF PKP2 KCNJ2 ANK2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.09 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
2 transmembrane transport GO:0055085 10.08 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
3 potassium ion transport GO:0006813 9.92 KCNQ1 KCNJ2 KCNH2 KCNE2
4 potassium ion transmembrane transport GO:0071805 9.92 KCNQ1 KCNJ2 KCNH2 KCNE2
5 regulation of ion transmembrane transport GO:0034765 9.91 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
6 cellular response to drug GO:0035690 9.84 KCNQ1 KCNH2 KCNE2
7 potassium ion import across plasma membrane GO:1990573 9.81 KCNJ2 KCNH2 KCNE2
8 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.78 RYR2 CACNA1C ANK2
9 cardiac muscle contraction GO:0060048 9.78 SCN5A RYR2 KCNQ1 KCNH2
10 positive regulation of potassium ion transmembrane transport GO:1901381 9.77 KCNQ1 KCNJ2 KCNH2
11 potassium ion export across plasma membrane GO:0097623 9.77 KCNQ1 KCNH2 KCNE2
12 cardiac muscle cell action potential involved in contraction GO:0086002 9.77 SCN5A PKP2 KCNJ2 KCNE2 CACNA1C
13 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.76 RYR2 PKP2 CACNA1C
14 regulation of heart rate GO:0002027 9.76 SCN5A RYR2 RANGRF ANK2
15 regulation of cardiac muscle cell contraction GO:0086004 9.75 SCN5A KCNJ2 ANK2
16 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.74 KCNQ1 KCNH2 KCNE2
17 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.73 SCN5A KCNJ2 CACNA1C
18 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.73 SCN5A KCNQ1 KCNH2 KCNE2 ANK2 AKAP9
19 regulation of membrane repolarization GO:0060306 9.72 KCNQ1 KCNJ2 KCNH2 KCNE2 AKAP9
20 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.71 RYR2 PKP2 CACNA1C
21 membrane repolarization during action potential GO:0086011 9.71 KCNQ1 KCNJ2 KCNH2 KCNE2
22 positive regulation of heart rate GO:0010460 9.7 RYR2 KCNQ1
23 regulation of cardiac muscle contraction GO:0055117 9.7 RYR2 ANK2
24 membrane repolarization GO:0086009 9.7 KCNQ1 KCNH2 KCNE2
25 cardiac conduction GO:0061337 9.7 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
26 regulation of potassium ion transmembrane transport GO:1901379 9.69 KCNH2 KCNE2
27 membrane depolarization during action potential GO:0086010 9.69 SCN5A KCNH2
28 positive regulation of sodium ion transport GO:0010765 9.69 SCN5A PKP2
29 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.69 KCNQ1 KCNJ2 KCNH2
30 calcium ion transport into cytosol GO:0060402 9.68 RYR2 CACNA1C
31 cellular response to epinephrine stimulus GO:0071872 9.68 RYR2 KCNQ1
32 regulation of sodium ion transmembrane transport GO:1902305 9.68 SCN5A RANGRF
33 regulation of cardiac muscle cell action potential involved in regulation of contraction GO:0098909 9.67 RANGRF AKAP9
34 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.67 RYR2 ANK2
35 atrial cardiac muscle cell action potential GO:0086014 9.67 SCN5A KCNQ1 ANK2
36 positive regulation of potassium ion transmembrane transporter activity GO:1901018 9.66 ANK2 AKAP9
37 SA node cell action potential GO:0086015 9.66 SCN5A ANK2
38 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.65 SCN5A KCNQ1
39 membrane depolarization during SA node cell action potential GO:0086046 9.65 SCN5A ANK2
40 membrane depolarization during AV node cell action potential GO:0086045 9.65 SCN5A CACNA1C
41 sarcoplasmic reticulum calcium ion transport GO:0070296 9.64 RYR2 ANK2
42 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.63 SCN5A CACNA1C
43 regulation of atrial cardiac muscle cell action potential GO:0098910 9.63 RYR2 ANK2
44 regulation of SA node cell action potential GO:0098907 9.61 RYR2 ANK2
45 ventricular cardiac muscle cell action potential GO:0086005 9.5 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
46 regulation of heart rate by cardiac conduction GO:0086091 9.28 SCN5A PKP2 KCNQ1 KCNJ2 KCNH2 KCNE2

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.76 SCN5A RYR2 KCNQ1 CACNA1C
2 ion channel activity GO:0005216 9.72 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
3 potassium channel activity GO:0005267 9.69 KCNQ1 KCNH2 KCNE2
4 voltage-gated potassium channel activity GO:0005249 9.67 KCNQ1 KCNH2 KCNE2
5 scaffold protein binding GO:0097110 9.65 SCN5A KCNQ1 KCNH2
6 delayed rectifier potassium channel activity GO:0005251 9.61 KCNQ1 KCNH2 KCNE2
7 protein kinase A regulatory subunit binding GO:0034237 9.58 RYR2 KCNQ1 AKAP9
8 inward rectifier potassium channel activity GO:0005242 9.54 KCNJ2 KCNH2 KCNE2
9 protein kinase A catalytic subunit binding GO:0034236 9.52 RYR2 KCNQ1
10 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.43 KCNQ1 KCNH2 KCNE2
11 voltage-gated ion channel activity GO:0005244 9.43 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
12 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.33 KCNQ1 KCNJ2 KCNH2
13 ion channel binding GO:0044325 9.23 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNE2

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....